Day: August 6, 2025

OAK RIDGE, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) — Oak Ridge Financial Services, Inc. (“Oak Ridge”; the “Company”) (OTCPink: BKOR), the parent company of Bank of Oak Ridge (the “Bank”), is pleased to share recent leadership transitions that reflect the organization’s continued growth and long-term strategic vision. Effective July 22nd, 2025, Tom Wayne was promoted to Chair of the Board of Directors, and Doug Boike transitioned into the role of Vice-Chair & Lead Director. Tom Wayne, who continues to serve as Chief Executive Officer and has long served as a member of the Board of Directors, brings a legacy of proven leadership, strategic insight, and deep commitment to the bank’s mission. His promotion to Chair recognizes his instrumental role in the organization’s success and further strengthens the bank’s governance and strategic...

Beijing/Hong Kong, Aug. 06, 2025 (GLOBE NEWSWIRE) — KUKE Music (NYSE: KUKE), a world-leading classical music content service provider, today announced a strategic collaboration with Naxos Music Group, the world’s largest independent classical music group. With a catalog of over 3 million audio tracks spanning more than 100 countries and regions, Naxos is the undisputed global leader in classical music. Under this partnership, Naxos will leverage its unparalleled content resources and service infrastructure to support KUKE Music’s exploration of artificial intelligence (AI) innovations, blockchain and RWA (Real World Assets) in classical music. The collaboration centers on building a blockchain- and AI-powered “Music LEGO Engine” designed to fundamentally revolutionize the creation, rights verification, application,...

SINGAPORE, Aug. 06, 2025 (GLOBE NEWSWIRE) — INNEOVA Holdings Limited (Nasdaq: INEO, “INNEOVA Holdings” or the “Company”) will hold its 2025 Annual General Meeting of Shareholders (the “AGM”) at 14 Ang Mo Kio Street 63, Singapore 569116 at 10 a.m. (Singapore Time) on August 25, 2025 (which is 10 p.m. (Eastern Daylight Time) on August 24, 2025). Holders of the Company’s ordinary shares listed in the register of members of the Company at the close of business on July 31, 2025 (Singapore Time) are entitled to receive notice of, and vote at, the AGM or at any adjournment or postponement that may take place. Copies of the Notice of the AGM, which sets forth the resolutions to be proposed and for which adoption from shareholders is sought, the Proxy Statement, and the Proxy Card are available on the Investor Relations...

06 August 2025 PayPoint Plc (the “Company”) Result of 2025 AGM The Company announces that the results of the Company’s Annual General Meeting held today, 06 August 2025, at 1 The Boulevard, Shire Park, Welwyn Garden City, Hertfordshire AL7 1EL were as follows:Resolutions Votes For 1 % Votes Against % Total Votes % of Issued Share Capital Voted Votes Withheld 21. To receive the annual report and accounts for theyear ended 31 March 2025 49,707,068 99.94 29,622 0.06 49,736,690 71.20% 349,5102. To approve the directors’ remuneration report for the year ended 31 March 2025 47,975,960 95.81 2,098,763 4.19 50,074,723 71.69% 11,4773. To declare a final dividend of 19.6 pence per ordinary share of the Company for the year ended 31 March 2025 50,062,646 99.96 21,994 0.04 50,084,640 71.70% 1,5604. To re-elect Giles Kerr as a director...

TORONTO, Aug. 06, 2025 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM”) is pleased to report that the condition to the proposed acquisition by DPM of Adriatic Metals plc (“Adriatic”), previously announced on June 13, 2025 (the “Transaction”) with respect to receiving the approval of the Transaction by the Competition Council of Bosnia and Herzegovina in accordance with the Bosnian Competition Act has now been satisfied. The parties are able to proceed with the Transaction subject to obtaining all applicable shareholder approvals and the approval of the High Court of Justice in England and Wales, the delivery of a copy of the High Court of Justice’s order to the Registrar of Companies in England and Wales and satisfying all other conditions. In connection with the upcoming special meeting of shareholders to be...

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) — EXL [NASDAQ: EXLS], a global data and AI company, has been recognized as a Market Leader in the HFS Research Horizons Insurance Services 2025 report. The report ranks 24 leading insurance providers across their value propositions, execution and innovation capabilities, go-to-market strategy, and market impact. The Market Leader designation is the report’s highest distinction. “The insurance industry stands at a pivotal crossroads, where operational efficiency, enhanced stakeholder experiences, and ecosystem-driven innovation are no longer optional—they are the defining horizons for carriers looking to lead in a rapidly evolving market,” said Tony Filippone, chief research officer, HFS Research. “We proudly recognize EXL as a Market Leader and look forward to their continued innovation...

Regulatory filing marks significant milestone for medication designed to provide once-daily, entire active-day symptom control in ADHD patients KANSAS CITY, Kan., Aug. 06, 2025 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for CTx-1301(dexmethylphenidate HCl), the company’s lead asset for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). CTx-1301 is a novel, extended-release tablet formulation of dexmethylphenidate designed to deliver fast onset, entire active-day efficacy, and a smooth pharmacokinetic...

Yokneam Illit, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) — Wearable Devices Ltd. (the “Company” or “Wearable Devices”) (Nasdaq: WLDS, WLDSW), a technology growth company specializing in artificial intelligence (“AI”)-powered touchless sensing wearables, today announced the launch of an innovative project to advance human-machine interfaces (“HMI”) for military applications. This cutting-edge initiative introduces a touchless neural control system that would enable soldiers to operate critical tactical systems seamlessly, enhancing operational efficiency and safety in high-stakes environments. Leveraging its proprietary neural interface technology, Wearable Devices is developing an innovative solution that would allow soldiers to interact with communication and control systems using intuitive gestures, without compromising their...

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline TherapyCHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the initiation of the Phase 1b trial of elraglusib in combination with Incyte’s PD-1 inhibitor, retifanlimab, and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy in advanced pancreatic adenocarcinoma. The trial is being conducted in collaboration with UPMC Hillman Cancer Center and Incyte Corporation. The Investigator-Initiated Phase 1b open-label, single-arm RiLEY...

Presented data highlights the potential of Annamycin for treating broad range of human cancers, including high-need oncology indications  Annamycin currently in late-stage clinical development in combination with cytarabine for the treatment of AML; Anticipated preliminary data readout in 2H 2025 HOUSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the presentation of encouraging preclinical data for its lead drug candidate, Annamycin, also known by its non-proprietary name of naxtarubicin, which demonstrated significant efficacy against various primary and metastatic liver cancers, including hepatocellular carcinoma (HCC), colorectal...